TABLE 1.
Characteristics of the 82 people with Parkinson's disease who we compared effects of the ABC‐C program on improvement in dual‐task cost on gait speed (mean ± SD)
| Characteristics | Freezers (n = 39) | Nonfreezers (n = 43) | p value |
|---|---|---|---|
| Men/women (number) | 30/9 | 24/19 | n/a |
| Age (years) | 68.1 (7.0) | 69.2 (8.0) | .484 |
| Height (cm) | 175.3 (9.6) | 172.4 (9.7) | .189 |
| Body mass (kg) | 80.5 (14.1) | 77.9 (16.4) | .438 |
| MoCA (score) | 25.6 (3.8) | 25.8 (3.2) | .821 |
| Disease duration (years) | 8.6 (5.5) | 4.4 (3.7) | <.001 |
| Hoehn and Yahr (a.u.) | 2.3 (0.6) | 2.1 (0.5) | .185 |
| MDS‐UPDRS motor (score) | 46.0 (12.7) | 38.3 (10.2) | <.001 |
| LEDD (mg/day) | 820.3 (984.2) | 535.3 (292.0) | .092 |
| PIGD (score) | 6.2 (2.9) | 4.4 (2.3) | .002 |
| PIGD subtype (%) | 82.1 | 46.5 | n/a |
| NFoGQ (score) | 13.8 (5.5) | n/a | n/a |
| Dual‐task cost on gait speed (%) | −18.0 (10.1) | −13.9 (9.8) | .030 |
Note: Values in bold signifies that p‐value is less than .05.
Abbreviations: a.u., arbitrary unit; LEDD, levodopa equivalent daily dose; MDS‐UPDRS‐III, Movement Disorders Society Unified Parkinson's Disease Rating Scale motor subscale; MoCA, Montreal Cognitive Assessment; n/a, not applicable; NFoGQ, new freezing of gait questionnaire; PIGD, postural instability and gait disorder.